Metabasis Therapeutics: Another Biopharma Microcap Implodes
by Douglas A. McIntyre
24/7 Wall St.
Metabasis Therapeutics (MBRX) is off 56% to $3 after its diabetes drug candidate CS-917 failed to significantly lower blood sugar in a mid-stage trial. The company has traded as high as $8.64 in the last year.
It is another example of the "one trick pony" microcap biopharma's that have nothing to offer but a one product trial. In the last quarter, the company lost over $9 million on revenue of $3.4 million.
Continue article at 247WallSt.com
24/7 Wall St. is a regular contributor to BioHealth Investor
______________
24/7 Wall St.
Metabasis Therapeutics (MBRX) is off 56% to $3 after its diabetes drug candidate CS-917 failed to significantly lower blood sugar in a mid-stage trial. The company has traded as high as $8.64 in the last year.It is another example of the "one trick pony" microcap biopharma's that have nothing to offer but a one product trial. In the last quarter, the company lost over $9 million on revenue of $3.4 million.
Continue article at 247WallSt.com
24/7 Wall St. is a regular contributor to BioHealth Investor
______________
posted by Nico at
9:52 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home